Appili Therapeutics secures $3.27 mln in seed financing
Appili Therapeutics Inc, a Halifax-based anti-infective pharmaceutical development company, has raised $3.27 million in seed-stage financing. The investors included Canadian venture capital firm Innovacorp, a number of undisclosed private investors, and federal government agencies, including the Atlantic Canada Opportunities Agency (ACOA). Founded last year with the support of Canadian healthcare investment bank Bloom Burton & Co, Appili is a developer of novel therapeutics for infectious disease. The funds raised will be used to advance development of its two antibiotic programs and move towards clinical studies.
25 May 2016•3 mins read
